{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:39:01Z","timestamp":1792089541695,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Untreated opioid use disorder (OUD) in pregnancy is associated with adverse obstetrical outcomes, maternal morbidity, and maternal mortality. This article will inform clinicians about the use of monthly extended\u2010release buprenorphine (BUP\u2010XR, SUBLOCADE\u00ae) to treat OUD during pregnancy and postpartum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined the use of monthly BUP\u2010XR during pregnancy in patients with OUD, summarizing case studies (<jats:italic>N<\/jats:italic>\u2009=\u20094) from clinical practice, reviewing &gt;5 years of pregnancy and postpartum surveillance data (quantitative [<jats:italic>N<\/jats:italic>\u2009=\u2009322] and qualitative) and relevant literature in PubMed (<jats:italic>N<\/jats:italic>\u2009=\u20094).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clinical practice case studies highlight the experience from four pregnant patients with OUD who received monthly BUP\u2010XR. All four neonates were delivered full\u2010term with normal birthweight, no fetal anomalies, and no medication required for neonatal opioid withdrawal syndrome. Additionally, over 300 pregnancies have been reported through postmarketing surveillance, of which 68 have known outcomes consistent with information described in the product label. Findings from literature, postmarketing surveillance, and clinical practice case studies were consistent with the established safety profile of buprenorphine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and Scientific Significance<\/jats:title><jats:p>This study addresses a lack of knowledge of treatment of pregnant individuals with OUD and draws on relevant experience from prescribers treating patients with monthly BUP\u2010XR during pregnancy and postpartum. These data support consideration of implementing BUP\u2010XR as part of evidence\u2010based practice that prioritizes OUD treatment access, patient stability, and patient choice during the perinatal period. Three sources of data illustrate that the use of monthly BUP\u2010XR during pregnancy has demonstrated no increased risk and is consistent with the established buprenorphine safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.70034","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:19:58Z","timestamp":1745885998000},"page":"485-494","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Monthly buprenorphine depot injection (SUBLOCADE\u00ae) for opioid use disorder during pregnancy"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-5670","authenticated-orcid":false,"given":"Melinda","family":"Ramage","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Mountain Area Health Education Center Biltmore Forest North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Bishop","sequence":"additional","affiliation":[{"name":"Indivior Inc North Chesterfield Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikki","family":"Mangano","sequence":"additional","affiliation":[{"name":"Indivior Inc North Chesterfield Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baher","family":"Mankabady","sequence":"additional","affiliation":[{"name":"Indivior Inc North Chesterfield Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Provisional drug overdose death counts","author":"Ahmad FB","year":"2024"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","unstructured":"HiraiAH KoJY OwensPL StocksC PatrickSW.Neonatal abstinence syndrome and maternal opioid\u2010related diagnoses in the US 2010\u20132017.JAMA.2021;325(2):146\u2010155.doi:10.1001\/jama.2020.24991","DOI":"10.1001\/jama.2020.24991"},{"key":"e_1_2_9_4_1","unstructured":"Centers for Disease Control and Prevention. Pregnancy\u2010related deaths: data from maternal mortality review committees in 36 US States 2017\u20132019. May 28 2024. Accessed February 12 2025.https:\/\/www.cdc.gov\/maternal-mortality\/php\/data-research\/mmrc-2017-2019.html"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.17045"},{"key":"e_1_2_9_6_1","unstructured":"American Medical Association. Improving access to care for pregnant and postpartum people with opioid use disorder: recommendations for policymakers. January 19 2024. Accessed February 12 2025.https:\/\/end-overdose-epidemic.org\/wp-content\/uploads\/2024\/02\/AMA-Manatt-2024-Improving-Access-to-Care-Pregnant-Parenting-People-with-SUD.pdf"},{"key":"e_1_2_9_7_1","unstructured":"Substance Abuse and Mental Health Services Administration Clinical Guidance. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. January 2018. Accessed February 20 2025.https:\/\/library.samhsa.gov\/product\/clinical-guidance-treating-pregnant-and-parenting-women-opioid-use-disorder-and-their"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100179"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_2_9_10_1","volume-title":"Guidelines for the identification and management of substance use and substance use disorders in pregnancy","author":"World Health Organization","year":"2014"},{"key":"e_1_2_9_11_1","unstructured":"US Food and Drug Administration News Release. FDA approves first once\u2010monthly buprenorphine injection a medication\u2010assisted treatment option for opioid use disorder. US FDA; November 30 2017. Accessed February 12 2025.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-once-monthly-buprenorphine-injection-medication-assisted-treatment-option-opioid"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00957-0"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1052113"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"e_1_2_9_15_1","volume-title":"Prescribing information","author":"SUBLOCADE\u00ae","year":"2002"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01406-7"},{"key":"e_1_2_9_17_1","unstructured":"SUBUTEX\u00ae 300 MG PROLONGED\u2010RELEASE SOLUTION FOR INJECTION (SUBLOCADE\u00ae). Summary of Product Characteristics. Indivior UK Limited; January 6 2025. Accessed February 12 2025.https:\/\/products.mhra.gov.uk\/"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","unstructured":"HubbellA AghentaE JonesC SpeckerS.Extended\u2010release buprenorphine in pregnancy.Am J Addict.2024;33(3):354\u2010356.doi:10.1111\/ajad.13518","DOI":"10.1111\/ajad.13518"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3127676"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004126"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005319"},{"key":"e_1_2_9_22_1","unstructured":"DinataleM. The Pregnancy and Lactation Labeling Rule (PLLR). United States Food and Drug Administration Pediatric Advisory Committee Meeting; September 14 2016. Accessed February 12 2025.https:\/\/www.fda.gov\/media\/100406\/download#:~:text=www.fda.gov -Conclusion&text=The%20PLLR%20provides%20a%20more when%20data%20are%20not%20available"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-029074"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000308"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-023-03614-7"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-020-00221-z"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.70034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:04:53Z","timestamp":1757419493000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.70034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/ajad.70034"],"URL":"https:\/\/doi.org\/10.1111\/ajad.70034","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"2024-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}